The biotech company argenx is witnessing a period of highs and lows. Their drug Vyvgart's study for thyroid eye disease was halted permanently after failing to deliver satisfactory results. Since then, the company's stock price fell. However, their plans to expand the usage of this immune system drug continues. Despite this disappointing result, argenx's stock price target expanded from $860 to $925 at RBC Capital, receiving a buy rating from Bank of America Securities. Additionally, argenx progresses with its Phase 2 study on ARGX-119 for Pediatric SMA, showing signs of growth and recovery.
Likewise, the company inks a $1.5B pact with Unnatural Products to progress macrocyclic peptides. They also have a global partnership with FUJIFILM Biotechnologies. By achieving record sales and having strategic plans for pipeline advancements, argenx has demonstrated its resilience in the face of setbacks. Furthermore, the stock massed positive interest after Vyvgart showcased positive results from the ADAPT SERON study, implying a strong outlook on Vyvgart's sales future.
argenx News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 20 Dec 2025 06:15:00 GMT - Rating 5 - Innovation -1 - Information 7 - Rumor 4
